What To Do When The US Attorney Calls
This article was originally published in RPM Report
Executive Summary
Attitude counts, federal prosecutor Michael Loucks says in an interview with The RPM Report. When senior management makes a commitment to correct wrongdoing, prosecutors are impressed.
You may also be interested in...
The Era of Big Pharma Fraud Cases Is Ending, Former US Attorney Loucks Says, But It May Go Out With A Bang
The pace of whistleblower cases against Big Pharma companies is winding down, former prosecutor says. It may not seem that way, with a full pipeline of pending investigations likely to dominate the headlines for months or even years to come, but Big Pharma is finally coming into compliance. This era may end with a bang: Loucks believes there is significant pressure to exclude a corporation for fraud.
Changing of the Guard in Health Care Fraud: An Interview With Michael Loucks
Michael Loucks stepped down as acting US Attorney at the end of 2009, after a career that put him at the center of many of the largest health care fraud prosecutions in the pharmaceutical industry. We spoke to him about what happens next, for industry, for prosecutors-and for him.
Bextra Settlement Coming Soon: Industry Should Brace for Impact
Record setting $2.3 billion payment is afterthought in context of Pfizer/Wyeth merger, but the Bextra and recent Zyprexa settlement will have far-reaching implications. In economic terms, the first two cases of 2009 exceed the total recoveries of the last 13 pharma marketing settlements. But the big impact may be political: the cases involve a volatile mix of marketing abuses and drug safety